New pan-tumour PBS listing expands access to immunotherapy
The listing follows the earlier pan-tumour PBS approval of nivolumab and ipilimumab and helps address a longstanding challenge for people with rare cancers, where access to funded treatment has often lagged behind more common tumour types. For some patients, this may provide an important new treatment option where choices have previously been limited.
For cancer nurses, the change reflects the increasingly complex and personalised nature of cancer treatment. Nurses are playing a growing role in helping patients understand why a treatment more commonly associated with another cancer may be relevant to them, supporting conversations around biomarker and genomic testing, and providing education about immunotherapy, treatment expectations and potential immune-related toxicities.
It is another reminder of the importance of building confidence in precision cancer medicine across the cancer nursing workforce. As treatment becomes increasingly guided by molecular and tumour characteristics, cancer nurses will be central to translating these advances into information patients can understand and care they can safely navigate.
